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Intravenous itraconazole for treating invasive pul-
monary aspergillosis in neutropenic patients with
acute lymphoblastic leukemia
Aspergillus infection is associated with a high
mortality rate in immunocompromised hosts;
more effective drugs for this infection are needed.
Oral itraconazole has been studied in neutropenic
fungus-infected patients. Using a novel formula-
tion (intravenous) of itraconazole, we successfully
treated severe necrotizing pneumonias due to
Aspergillus species occurring during a post-
chemotherapy prolonged aplastic phase in two
patients with acute lymphoblastic leukemia.Haematologica 2007; 88:(1)e8-e9
Invasive pulmonary aspergillosis is an emerging com-
plication in patients with acute leukemia. Its increasing
incidence has been dramatically documented in the last
decade, in both ante- and post-mortem studies.1,2 The
overall response rates to conventional amphotericin B
(cAMB) is unsatisfactory, ranging between 35% and
45%; long-term therapy is badly tolerated owing to
nephro- and infusion-related toxicity.3 More effective
and less toxic drugs for this infection are needed. We
report the use of i.v. itraconazole for the treatment of
invasive pulmonary aspergillosis in two patients who
had undergone intensive chemotherapy for acute lym-
phoblastic leukemia (ALL) and were subsequently
included in an international phase IV study (Protocol
ITR-INT-92; Sporanox IV, Janssen Pharmaceutica,
Beerse, Belgium).
Case report #1
Ph-positive ALL-L2 was diagnosed in a 39-year old
woman in November 1999. She proved to be resistant to
2 induction courses, and no bone marrow donor was
available. In June 2000, she received additional
chemotherapy (cytarabine 11 gr daily for 4 days and
idarubicin 22 mg daily for 3 days). Antimicrobial prophy-
laxis with ciprofloxacin and fluconazole was given. After
10 days of severe neutropenia, she started having high
fever followed by chest pain, cough, dyspnea, and mod-
erate hypoxia, and received broad-spectrum antibiotics.
A week later the persistence of symptoms and the
appearance of pulmonary infiltrates (Figure 1A) led to
antifungal treatment with i.v. cAMB 1.5 mg/Kg/day and
G-CSF 5 µg/Kg/day. After 10 days, cAMB was stopped
because of persisting symptoms and onset of refractory
severe hypokalemia. Intravenous itraconazole was start-
ed at 400 mg daily on the first 2 days, followed by 200
mg daily for 12 days. The clinical course rapidly
improved with symptom regression, although recovery
from neutropenia occurred 2 weeks later. A second
course of i.v. itraconazole (compassionate use) was given
(same dosage and duration), for persisting pulmonary
infiltrates (Figure 1B). In September 2000, the patient
was discharged in complete hematological and cytoge-
netic remission from ALL; itraconazole was continued
orally (5 mg/Kg twice a day). A month later, she under-
went surgical curettage of a peripheral residual nodule:
pathologic examination and culture of the surgical sec-
tion documented Aspergillus fumigatus infection. In
January 2001 a course of consolidation chemotherapy
was given, but the patient died of leukemia relapse
resistant to salvage chemotherapy in June 2001; neither
signs nor symptoms of pulmonary infection recurred
after consolidation and salvage treatments.
Case report #2
In July 2000 a 43-year-old woman with ALL-L1 was
admitted for induction chemotherapy including L-
asparaginase, vincristine, daunorubicin and prednisone
(GIMEMA 0496 Protocol). Standard antimicrobial pro-
phylaxis was given. After 10 days of moderate neutrope-
nia, she started having high fever followed by chest pain,
cough, dyspnea and moderate hypoxia, and received
meropenem 3 gr daily, amikacin 1 gr daily and
teicoplanin 400 mg daily. A week later, the persistence of
symptoms and the appearance of pulmonary infiltrates
(Figure 1C) prompted antifungal treatment (i.v. itracona-
zole 400 mg daily for 2 days, followed by 200 mg daily
for 12 days). After starting itraconazole the clinical
course rapidly improved with symptom regression. No
pathogens were found in the culture of bronchoalveolar
lavage. Two weeks later recovery from neutropenia
occurred and the patient was discharged. Itraconazole
was continued orally (5 mg/Kg twice a day) for persist-
ing pulmonary infiltrates, likely due to Aspergillus
species (Figure 1D). A few months later a CT-scan found
no pulmonary infiltrates. She underwent consolidation
and maintenance chemotherapy; neither signs nor symp-
toms of pulmonary infection recurred. The patient is in
continuous complete hematological remission from ALL
and off-therapy.
Only a few drugs are effective for treating invasive
pulmonary aspergillosis, including conventional and
lipid-based AMB, itraconazole, and, more recently,
voriconazole and caspofungin.4,5 Few data are available
on the use of i.v. itraconazole for invasive pulmonary
aspergillosis in immunocompromised hosts.6 Our
patients had a proven (case #1) or possible (case #2) inva-
sive pulmonary aspergillosis;7,8 within the frame of a trial
on the use of i.v. itraconazole in invasive fungal infec-
Figure 1. Changing characteristics of invasive pulmonary
aspergillosis on computed tomography scans. (A) Subpleural large
parenchymal masses with a surrounding halo of ground-glass
attenuation (halo sign), in the right lung; a small nodular lesion in
the left lung. (B) Two weeks later, a fungus ball inside the right
lesion. (C) Large triangular infiltrate in the left lung, and bilateral
pleural effusion. (D) Two weeks later, cavitation described as the
air-crescent sign inside the parenchymal lesion.
tions, this drug was introduced after informed consent as
first-line treatment in case 2 and after failure of cAMB in
case #1. During the following 2 weeks, even in the
absence of neutrophil recovery, infectious symptoms
completely disappeared in both cases. Complete disap-
pearance of the pulmonary infection was achieved after
switching to high-dose oral itraconazole (Sporanox Oral
Solution),9 combined with surgical curettage in one case.
At the dose used, i.v. itraconazole did not show any side-
effect or hematological toxicity. In conclusion, this drug
proved to be effective and well tolerated for the manage-
ment of life-threatening invasive pulmonary aspergillo-
sis. These observations warrant further investigations of
i.v. itraconazole use in neutropenic patients with acute
leukemia and Aspergillus infection. 
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